Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes
Robert L. Hollis,Mignon D. J. M. van Gent
DOI: https://doi.org/10.3389/fonc.2024.1519252
IF: 4.7
2024-12-10
Frontiers in Oncology
Abstract:Ovarian cancer is an umbrella term for a multitude of distinct disease entities identified in and around the ovary, fallopian tube and peritoneum. These include epithelial ovarian cancers (ovarian carcinomas), of which there are six major types: high grade serous (HGSOC), endometrioid (EnOC), clear cell (CCOC), mucinous (MOC), low grade serous (LGSOC) and ovarian carcinosarcoma (OCS) [1]. Non-epithelial cancers include malignant germ cell tumours (teratoma, dysgerminoma, yolk sac tumour and others), sex chord stromal tumours (granulosa cell tumours, Sertoli-Leydig cell tumours and more), Brenner tumours and mesenchymal tumours, among others [2]. These various types have been shown to arise from distinct developmental origins, have unique molecular profiles, varied response rates to conventional and targeted therapies, and distinct overall clinical behaviour [2][3][4][5][6][7][8][9].HGSOC is by far the commonest, and the vast majority of research has accordingly focussed on this tumour type. These studies have advanced our knowledge of HGSOC at the genomic, transcriptomic and proteomic levels [4,[10][11][12], identifying therapeutically-exploitable disease biology that has led directly to the design and utilisation of additional targeted treatment strategies, including poly(ADPribose) polymerase (PARP) inhibitors [13,14]. After approximately 30 years of limited progress in improving ovarian cancer survival, the integration of these agents into routine clinical practice is now shifting the survivorship landscape in HGSOC.However, progress within the other, less common, ovarian cancer types has been lacking, and many remain critically understudied with a corresponding lack of targeted therapeutic options. Indeed, the fundamental molecular landscape in many of these tumour types have either only recently been established, or have yet to be described in large numbers of samples [7,[15][16][17][18]. In this Research Topic, we aimed to provide a platform for communication of research in uncommon and understudied forms of ovarian cancer, in the hope of advancing our understanding of these discrete disease entities.OCS represents approximately 4% of ovarian cancer diagnoses, is characterised by the presence of both high grade carcinomatous and high grade sarcomatous components [2], and is exceptionally aggressive (median survival <2 years) with higher levels of intrinsic chemoresistance compared to HGSOC [19].Three contributions on OCS are presented in this collection that augment our current understanding of this uncommon and aggressive tumour type. Zheng et al. report a case of a 76 year-old female diagnosed with FIGO stage IIIC OCS [20]; the report provides an excellent example of OCS histopathology, with contrasting cytokeratin immunohistochemical profiles between carcinomatous (CK+) and sarcomatous components (CK-), but shared aberrant p53 immunophenotype indicated of TP53 mutation. They also demonstrate the presence of chondrosarcomatous differentiation, which has been reported as the most frequent heterologous element in OCS [19].In a clinical cohort study, McFarlane et al. make use of two contrasting data sources to compare the clinical behaviour of OCS patients versus those with other ovarian carcinomas [9]: one from The Edinburgh Ovarian Cancer Database, the other from Surveillance Epidemiology and End Results (SEER) database. The findings identify OCS as the histotype with the least favourable overall survival profile, and this is especially the case in the context of early stage diagnosis, with FIGO stage I-II OCS patients demonstrating a median survival time of just two years in their primary cohort. The study also demonstrates that OCS patients represent an older patient population compared to other histotypes, with the median age at diagnosis being 67 years.Finally, a molecular profiling study is presented by Dhillon et al., analysing a cohort of OCS samples by targeted sequencing and immunohistochemical profiling [21]. They show that the TP53 mutation rate in this tumour type is high, but that a minority of cases (15-20%) are p53 wildtype; the p53 wildtype population demonstrated poorer survival, and this is one of the first reported molecular prognostic factors in OCS. Moreover, they demonstrate that a proportion of OCS harbour BRCA1/2 mutation, highlighting the potential for some OCS patients to benefit from PARP inhibition. The BRCA1/2-mutant cases were suggested to experience more favourable survival, with 100% 3-year survival, though the number of BRCA1/2-mutant cases was limited.LGSOC accounts for 3-5% of ovarian cancer diagnoses, demonstrates high levels of intrinsic chemoresistance, and affects younger women compared to HGSOC. Advancements have recently been made in treatment of LGSOC, with MEK inhibitors now recognised as a useful therapeutic option at recurrence [22], and endocrine maintenance therapy demonstrating substantial clinical ac -Abstract Truncated-
oncology